At the 14th World Congress on Pain, Spinifex announced positive results from a Phase 2 clinical trial evaluating EMA401 for the treatment of postherpetic neuralgia (PHN). An international, multicenter, double-blind, placebo-controlled, randomized trial evaluating EMA401, met its primary endpoint — reduction in mean daily pain score versus placebo over the last week of 28 days of treatment. Results show a statistically significant and clinically meaningful reduction in mean pain intensity from baseline to Week 4 for patients on active treatment when compared to placebo. On an intent to treat basis, the mean pain intensity reduction from baseline after four weeks treatment was as follows: EMA401: -2.34; placebo: -1.64; P=0.006. A significantly greater proportion of patients on active treatment reported a more than 30% reduction in mean pain intensity score compared to baseline (i.e., responder rate) (EMA401: 56.5%; placebo: 34.1%; P=0.003), meeting a key secondary endpoint.
EMA401 is an angiotensin II type 2 (AT2) receptor antagonist believed to exert effects on neuropathic and inflammatory pain.
For more information, visit www.spinifexpharma.com.au.